ライフサイエンスコーパス: urinary tract

1 odulation, to treat pathologies of the lower urinary tract.

2 having a similar bacterial burden within the urinary tract.

3 s nephron and from other cells that line the urinary tract.

4 h adhesins that bind mucosal surfaces of the urinary tract.

5 les in mediating adhesion of bacteria to the urinary tract.

6 s were then obtained to further evaluate the urinary tract.

7 tes adherence to the epithelium of the upper urinary tract.

8 ant for E. faecium to cause infection in the urinary tract.

9 kidney injury and bacterial infection in the urinary tract.

10 to attenuate innate immune responses in the urinary tract.

11 nase-associated lipocalin, or 24p3) into the urinary tract.

12 tection against pathogen colonization of the urinary tract.

13 high bacterial loads during infection of the urinary tract.

14 h the constantly changing environment of the urinary tract.

15 among the most common pathogens of the human urinary tract.

16 Urothelium is the protective lining of the urinary tract.

17 balance, and clearance of bacteria from the urinary tract.

18 the location of ISL1 activity in the forming urinary tract.

19 the limiting of bacterial growth within the urinary tract.

20 ial cells of the gastrointestinal and genito-urinary tracts.

21 gans were the liver (24%), kidney (16%), and urinary tract (15%).

22 common infection sources were lung (43%) and urinary tract (17%); in 22% of cases, infection source r

23 esponsible for a large proportion of E. coli urinary tract and bloodstream infections, and they diffe

24 ic multidrug resistant clone associated with urinary tract and bloodstream infections.

25 ulates state-dependent reflexes in the lower urinary tract and contribute to our understanding of the

26 , thereby suppressing innate immunity in the urinary tract and enhancing persistence in the kidneys.

27 verse bacteria cause infection stones in the urinary tract and form crystalline biofilms on indwellin

28 nderstanding the neural control of the lower urinary tract and how dysfunction arises in disease stat

29 Escherichia coli (UPEC), a leading cause of urinary tract and invasive infections worldwide, is rapi

30 floxacin completely eradicates UPEC from the urinary tract and prevents the development of relapsing

31 ted with abnormalities of metabolism and the urinary tract, and the possible presence of rare genetic

32 ts: 2080 patients with congenital kidney and urinary tract anomalies and 22,094 controls.

33 It comprises complex urinary tract anomalies, bilateral undescended testis an

34 Children with urinary tract anomalies, premature birth, or major comor

35 ndrome and in sporadic congenital kidney and urinary tract anomalies.

36 Structural birth defects in the kidney and urinary tract are observed in 0.5% of live births and ar

37 ro and in animal models for disseminated and urinary tract C. glabrata infection.

38 Congenital anomalies of the kidneys and urinary tract (CAKUT) are the leading cause of CKD in ch

39 Congenital anomalies of the kidneys and urinary tract (CAKUT) are the most common cause of chron

40 Congenital anomalies of the kidney and urinary tract (CAKUT) are the most common cause of CKD i

41 Congenital anomalies of the kidneys and urinary tract (CAKUT) comprise a large spectrum of conge

42 Congenital anomalies of the kidney and urinary tract (CAKUT) occur in three to six of 1000 live

43 idence interval [95% CI], 0.8-2.2) for upper urinary tract cancer associated with long-term use of li

44 identified all histologically verified upper urinary tract cancer cases in Denmark between 2000 and 2

45 ses stratified by stage and subtype of upper urinary tract cancer revealed slight but nonsignificant

46 se of lithium (>/=5 years) and risk of upper urinary tract cancer using conditional logistic regressi

47 n long-term use of lithium and risk of upper urinary tract cancer, including renal cell cancer and ca

48 t associated with an increased risk of upper urinary tract cancer.

49 (A57G and F82V) have also been identified in urinary tract cancers and myeloid malignancies.

50 We assessed risk for urinary tract cancers in kidney recipients with or witho

51 scribe detection of BK polyomavirus (BKV) in urinary tract cancers in kidney transplant recipients, s

52 iding the unnecessary use of intravenous and urinary tract catheters.

53 terial infections in humans are those of the urinary tract, caused chiefly by uropathogenic Escherich

54 The risk of developing upper urinary tract damage and renal failure is much lower in

55 ity and contributes to pathogenesis of lower urinary tract defects in human infants.

56 hich the pathogen enhances to persist in the urinary tract despite the host's robust immune response.

57 ptibility gene for CBE and as a regulator of urinary tract development.

58 = 98.7%; kappa = 0.97) and obstructive upper urinary tract disease (tau = 98.16%; kappa = 0.95) were

59 ociated with clinical failure, whereas early urinary tract drainage procedures (surgical, percutaneou

60 results have implications for understanding urinary tract dysfunction caused by neuropathy or nerve

61 ed with other developmental anomalies of the urinary tract, emphasising its etiology as a disorder of

62 data suggest that catheterization alters the urinary tract environment to promote MRSA CAUTI pathogen

63 ongenital anomalies affecting the kidney and urinary tract exhibited deletions and loss of function v

64 Foreign body in the lower urinary tract has a low incidence.

65 ificance of Alloscardovia omnincolens in the urinary tract has not been thoroughly evaluated.

66 ans, respiratory tract, female genitalia and urinary tract, HR values increased significantly from ne

67 ficant effects on colonization of the murine urinary tract in vivo.

68 ociated with polymicrobial infections of the urinary tract, indwelling catheters, and surgical wound

69 ryngitis (38 [14%] vs 36 [12%] vs 39 [15%]), urinary tract infection (19 [7%] vs 11 [4%] vs 13 [5%]),

70 a (4.5%), nonspecific chest pain (3.7%), and urinary tract infection (3.2%).

71 (58.98% vs 14.81%; OR, 8.53; CI, 7.41-9.83), urinary tract infection (38.41% vs 8.60%; OR, 7.81; CI,

72 ade >/=3 infections included pneumonia (8%), urinary tract infection (4%), and cellulitis (3%).

73 ower rates of ileus, Foley re-insertion, and urinary tract infection (all P < 0.01).

74 Catheter-associated urinary tract infection (CAUTI) is the commonest hospita

75 Catheter associated urinary tract infection (CAUTI) is the most common healt

76 is an emerging cause of catheter-associated urinary tract infection (CAUTI), which frequently progre

77 welling catheter use and catheter-associated urinary tract infection (CAUTI).

78 m and doripenem in patients with complicated urinary tract infection (cUTI), including acute pyelonep

79 The most common infections were urinary tract infection (cystitis) (34.9% vs 25.2%), cyt

80 Episodes of urinary tract infection (cystitis) occurred more often i

81 ions (OR = 7.0; CI, 1.7-28.3; P = .006), and urinary tract infection (OR = 0.04; CI, 0.3-0.9; P = .02

82 tected escherichelin during clinical E. coli urinary tract infection (UTI) and experimental human col

83 be used to monitor the onset or prognosis of urinary tract infection (UTI) and some sexually-transmit

84 signaling networks controlled by CD14 during urinary tract infection (UTI) are unknown.

85 ed a household in which 2 young children had urinary tract infection (UTI) caused by an extended-spec

86 ts presented to the ED with an ICD 9/10 code urinary tract infection (UTI) diagnosis during July 2015

87 Catheter-associated urinary tract infection (UTI) is a common device-associa

88 Urinary tract infection (UTI) is a major global infectio

89 gnosis of asymptomatic bacteriuria (ASB) and urinary tract infection (UTI) is based on the presence o

90 Urinary tract infection (UTI) is one of the most common

91 The contribution of genetic variation to urinary tract infection (UTI) risk in children with vesi

92 lthy adult women with a history of recurrent urinary tract infection (UTI) to receive a single inject

93 For urinary tract infection (UTI), a history of two or more

94 Secondary outcomes were symptomatic urinary tract infection (UTI), all-cause death, all-caus

95 et for uropathogenic E. coli (UPEC)-mediated urinary tract infection (UTI), its contribution to UPEC

96 ment of underlying ARD, and risk factors for urinary tract infection (UTI), were recorded.

97 sion in the kidney, we addressed its role in urinary tract infection (UTI), which remains largely unk

98 iption of uropathogens in women experiencing urinary tract infection (UTI)-like symptoms.

99 by Escherichia coli strains associated with urinary tract infection (UTI).

100 ory infection, intra-abdominal infection, or urinary tract infection (UTI).

101 Streptococcus agalactiae can cause urinary tract infection (UTI).

102 in vitro and disease severity in a model of urinary tract infection (UTI).

103 septic condition but has not been studied in urinary tract infection (UTI).

104 of abdominal pain, bloating, diarrhoea, and urinary tract infection [grade 3]; aneurysm [grade 4]),

105 best available therapy (137 with complicated urinary tract infection and 11 with complicated intra-ab

106 ger percent burn and with the development of urinary tract infection and sepsis postadmission, regard

107 ceftazidime-avibactam (144 with complicated urinary tract infection and ten with complicated intra-a

108 ic reflux in children who have had a febrile urinary tract infection be reduced, but this approach is

109 fumarate for 8 months presented with fever, urinary tract infection caused by Escherichia coli, anal

110 Our data reveal potential links for urinary tract infection development and several morbidit

111 rence to study medication, or development of urinary tract infection during the study.

112 Vesicoureteral Reflux trial and the Careful Urinary Tract Infection Evaluation Study).

113 strategy for patients suspected of having a urinary tract infection is to test for pyuria and bacter

114 t Escherichia coli and Enterococcus faecalis urinary tract infection isolates.

115 Moreover, in a murine urinary tract infection model, CFT073 infection rapidly

116 formation as well as attenuation in a murine urinary tract infection model.

117 oding a virulence factor in endocarditis and urinary tract infection models, has been shown to increa

118 ailable therapy in patients with complicated urinary tract infection or complicated intra-abdominal i

119 ients were aged 18-90 years with complicated urinary tract infection or complicated intra-abdominal i

120 would not increase the risk of developing a urinary tract infection or increase the burden of use to

121 nd no difference in complications, including urinary tract infection rates, between those using singl

122 e patients and in samples from patients with urinary tract infection using real-time reverse transcri

123 oodstream infection, and catheter-associated urinary tract infection was 14.7 per 1000 ventilator-day

124 bles, being married or having a history of a urinary tract infection was associated with lower urinar

125 ons were 14 versus 7 for catheter-associated urinary tract infection, 13 versus 8 for ventilator-asso

126 00 for community-acquired pneumonia, 112 for urinary tract infection, 83 for intra-abdominal infectio

127 elop a point-of-care susceptibility test for urinary tract infection, a disease that 100 million wome

128 ates of RTI, skin and soft-tissue infection, urinary tract infection, and bloodstream infection varie

129 gnoses as upper respiratory tract infection, urinary tract infection, and influenza-like illness occu

130 During experimental urinary tract infection, MAITs migrated to the bladder a

131 infection, ventilator-associated pneumonia, urinary tract infection, mean ventilator-free days, mean

132 ection (SSI), deep/organ-space SSI, any SSI, urinary tract infection, pneumonia, sepsis, deep venous

133 dependence, progressive renal insufficiency, urinary tract infection, stroke, venous thromboembolism,

134 her an E. faecalis or Pseudomonas aeruginosa urinary tract infection, suggesting a role for urinary a

135 s: pneumonia, surgical site infection (SSI), urinary tract infection, transfusion/bleed events, and a

136 use only, particularly for outcomes such as urinary tract infection, urethral injury and quality of

137 The effect of complications, such as urinary tract infection, venous thromboembolism, and myo

138 s a composite outcome of catheter-associated urinary tract infection, ventilator-associated pneumonia

139 Urinary tract infection-positive burn patients with alte

140 are test that can guide correct treatment of urinary tract infection.

141 antibiotic prophylaxis to prevent recurrent urinary tract infection.

142 a key factor for successful establishment of urinary tract infection.

143 , the only bacterial infection of concern is urinary tract infection.

144 cellular trap generation during experimental urinary tract infection.

145 nce type 131 (ST131) in treatment failure of urinary tract infection.

146 iously shown to be important in experimental urinary tract infection.

147 comprised rejection, acute tubular necrosis, urinary tract infection/pyelonephritis, viral nephritis,

148 quired bloodstream infection, pneumonia, and urinary tract infection; all-cause ICU mortality; and le

149 yuria and a diagnosis of a complicated lower-urinary-tract infection or pyelonephritis were randomly

150 ratory tract infection (3 [7%] vs none], and urinary tract infections (3 [7%] vs 1 [2%]).

151 ear, nose, and throat infections (55 [7%]), urinary tract infections (37 [5%]), and surgical-site in

152 e focused on the risk of catheter-associated urinary tract infections (CAUTI) caused by Escherichia c

153 n detecting the onset of catheter-associated urinary tract infections (CAUTIs) is also demonstrated b

154 am infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated

155 ot associated with melanoma risk, except for urinary tract infections (CLL/SLL), localized scleroderm

156 (n=10 [12%]), peripheral oedema (n=9 [11%]), urinary tract infections (n=9 [11%]), and orthostatic hy

157 s with antibiotic-resistant Escherichia coli urinary tract infections (odds ratio [OR] = 4.19; 95% co

158 ty (OR, 5.24; 95% CI, 2.15-12.77), recurrent urinary tract infections (OR, 0.97; 95% CI, 0.27-3.45),

159 Women suffering from recurrent urinary tract infections (rUTIs) are routinely treated f

160 Urinary tract infections (UTI) are one of the most commo

161 oli (UPEC) is the major cause of 150 million Urinary Tract Infections (UTI) reported annually world-w

162 richia coli (UPEC) accounts for 80 to 90% of urinary tract infections (UTI), and the increasing rate

163 s the major causative agent of uncomplicated urinary tract infections (UTI).

164 ned susceptibility of clinical isolates from urinary tract infections (UTIs) after 15 min of exposure

165 Urinary tract infections (UTIs) and sexually transmitted

166 richia coli strains from 10 men with febrile urinary tract infections (UTIs) and their female sex par

167 Urinary tract infections (UTIs) are a common occurrence

168 Urinary tract infections (UTIs) are a major burden to hu

169 Urinary tract infections (UTIs) are a microbial disease

170 Urinary tract infections (UTIs) are among the most commo

171 Urinary tract infections (UTIs) are among the most commo

172 Urinary tract infections (UTIs) are among the most commo

173 Urinary tract infections (UTIs) are common health-care-a

174 Urinary tract infections (UTIs) are common in both inpat

175 Urinary tract infections (UTIs) are frequent and lead to

176 Complicated urinary tract infections (UTIs) are frequent in immunosu

177 Urinary tract infections (UTIs) are frequently encounter

178 Urinary tract infections (UTIs) are one of the most comm

179 Urinary tract infections (UTIs) are potentially life thr

180 Urinary tract infections (UTIs) caused by uropathogenic

181 ntibiotics for recurrent multidrug-resistant urinary tract infections (UTIs) disrupt the gut microbio

182 Urinary tract infections (UTIs) occur predominantly in f

183 ble hematuria, migration, fragmentation, and urinary tract infections (UTIs) within 3 mo of transplan

184 of hospital-associated infections, including urinary tract infections (UTIs), bacteremia, and infecti

185 ExPEC causes the vast majority of urinary tract infections (UTIs), is a leading cause of a

186 nd long durations of therapy for symptomatic urinary tract infections (UTIs), yet large-scale evaluat

187 (UPEC) is the primary cause of uncomplicated urinary tract infections (UTIs).

188 nths) and prevalence of antibiotic-resistant urinary tract infections (UTIs).

189 (UPEC) bacteria are a causative pathogen of urinary tract infections (UTIs).

190 a significant number of catheter-associated urinary tract infections (UTIs).

191 The aRRs were increased particularly for urinary tract infections (UTIs, 1.41; 95% CI, 1.35 to 1.

192 dentification of microbial pathogens causing urinary tract infections allow prompt and specific treat

193 History A 52-year-old man with a history of urinary tract infections and a previous clinical diagnos

194 to identify potential mechanisms leading to urinary tract infections and associated morbidities in b

195 Escherichia coli associated with urinary tract infections and bacteremia has been intensi

196 ts when used in the treatment of complicated urinary tract infections and complicated intra-abdominal

197 23 individuals diagnosed with polymicrobial urinary tract infections and found that most interaction

198 well described for ExPEC strains that cause urinary tract infections and meningitis, they have not b

199 In addition, it resulted in a higher risk of urinary tract infections and need for transient self-cat

200 ome may be used to predict susceptibility to urinary tract infections and sepsis in burn patients.

201 extraintestinal sites to cause diseases like urinary tract infections and sepsis.

202 Lower urinary tract infections are among the most common human

203 Urinary tract infections are commonly caused by alpha-he

204 Urinary tract infections are considered among the most c

205 Urinary tract infections are one of the most common reas

206 ovel findings include clinically significant urinary tract infections by Actinomyces neuii (21%) and

207 Urinary tract infections caused by uropathogenic Escheri

208 Urinary tract infections caused by uropathogenic Escheri

209 wardship in the era of increasing numbers of urinary tract infections due to extensively drug-resista

210 The widespread occurrence of urinary tract infections has resulted in frequent antibi

211 Frequent antibiotic treatment of urinary tract infections has resulted in the emergence o

212 cherichia coli, the major causative agent of urinary tract infections in humans.

213 h of nine antibiotics that are used to treat urinary tract infections in minutes.

214 Urinary tract infections still remain a concern in febri

215 niae causes a wide range of infections, from urinary tract infections to pneumonia.

216 e, which had been standard treatment against urinary tract infections until widespread resistance dec

217 Urinary tract infections were more frequent in the onabo

218 ant pathogens responsible for intestinal and urinary tract infections, as well as sepsis and hemolyti

219 During Escherichia coli urinary tract infections, cells in the human urinary tra

220 enic E. coli (UPEC) is the dominant cause of urinary tract infections, clinically described as cystit

221 coli (UPEC), the primary causative agents of urinary tract infections, colonize and invade the epithe

222 for most spending related to admissions for urinary tract infections, dehydration, heart failure, an

223 ed 32 ventilator-associated pneumonia, eight urinary tract infections, five blood stream infections,

224 In human urinary tract infections, host cells release the antimic

225 Increased rates of Escherichia coli urinary tract infections, increasing resistance to ampic

226 a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), y

227 ommon agent of sepsis and community-acquired urinary tract infections, obtained during the course of

228 ve complications from BPH, such as recurrent urinary tract infections, refractory urinary retention,

229 nia, bacterial meningitis, yeast infections, urinary tract infections, tonsillectomy, childhood ear i

230 richia coli (UPEC), the predominant cause of urinary tract infections, undergoes a transient intracel

231 as associated with more frequent episodes of urinary tract infections, whereas other infections occur

232 ons-including 32 with bacteremia and 15 with urinary tract infections-and 190 without bacterial infec

233 ed intraabdominal infections, or complicated urinary tract infections.

234 (UPEC), which cause both acute and recurrent urinary tract infections.

235 arrhoea, injection-site nodules, nausea, and urinary tract infections.

236 er hipA mutants cause multidrug tolerance in urinary tract infections.

237 non-spore-forming rod, are presented here as urinary tract infections.

238 step-down oral therapy to treat complicated urinary tract infections.

239 and inguinal hernias but less than that for urinary tract infections.

240 12), headache (five and three vs eight), and urinary-tract infections (six and two vs two).

241 Treatment of complicated urinary-tract infections is challenging due to rising an

242 treatment of patients with complicated lower-urinary-tract infections or pyelonephritis.

243 ofloxacin in patients with complicated lower-urinary-tract infections or pyelonephritis.

244 tsS/BtsR importance during acute and chronic urinary-tract infections.

245 KEY POINTS: The lower urinary tract is regulated by reflexes responsible for m

246 Lower urinary tract (LUT) dysfunction is a common sequela of n

247 urden, with many defects affecting the lower urinary tract (LUT), genital tubercle and associated str

248 he importance of apoptotic modulation during urinary tract morphogenesis.

249 Nineteen patients had upper urinary tract multifocal atypia.

250 uded congenital anomalies of the kidneys and urinary tract (n = 637 [70.9%]), tubulointerstitial neph

251 SWS in discerning no, equivocal, or definite urinary tract obstruction (area under the ROC curve rang

252 aphic evidence of no, equivocal, or definite urinary tract obstruction (P > .5) or for median SWS mea

253 on but important cause of infravesical lower urinary tract obstruction that is more common in male ur

254 tigraphy (reference standard for presence of urinary tract obstruction).

255 epithelial cells in response to injury from urinary tract obstruction.

256 se model showed Isl1-expressing cells in the urinary tract of mouse embryos at E10.5 and distributed

257 nd how sensory disruption manifests in lower urinary tract pathophysiology.

258 ABSTRACT: Lower urinary tract reflexes are mediated by peripheral affere

259 urinary tract infections, cells in the human urinary tract release the antimicrobial protein sideroca

260 res from pathogens causing infections of the urinary tract show that the proposed approach is promisi

261 ory-confirmed infections (respiratory tract, urinary tract, skin or soft tissue), antibiotic resistan

262 ndins could be used to treat candidemia of a urinary tract source (CUTS) is unknown.

263 h hospital records to identify patients with urinary tract stones (N = 211,718) and cancer registrati

264 We analysed cancer risks in patients with urinary tract stones but some features of the generated

265 were more common in patients diagnosed after urinary tract stones compared to all patients.

266 alculated after the last medical contact for urinary tract stones.

267 of the female nurses had at least one lower urinary tract symptom, nearly 50% had incontinence sympt

268 Lower urinary tract symptoms (LUTS) are a range of irritative

269 tatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men.

270 Lower urinary tract symptoms among female nurses should not be

271 aimed to investigate the prevalence of lower urinary tract symptoms among female nurses, and the asso

272 . omnincolens is only rarely associated with urinary tract symptoms and in some patients may play a c

273 Nearly all older men will experience lower urinary tract symptoms associated with benign prostatic

274 ting behaviours exist among women, and lower urinary tract symptoms have a high prevalence and signif

275 We present a case report of AUV with lower urinary tract symptoms in a 6-year-old boy with complain

276 nship between toileting behaviours and lower urinary tract symptoms is unclear.

277 n on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms scales were used to assess the pa

278 However, lower urinary tract symptoms were not significantly associated

279 participants' toileting behaviours and lower urinary tract symptoms, respectively.

280 ry tract infection was associated with lower urinary tract symptoms.

281 ntly associated with susceptibility to lower urinary tract symptoms.

282 ation between toileting behaviours and lower urinary tract symptoms.

283 ation between toileting behaviours and lower urinary tract symptoms.

284 period were negatively associated with lower urinary tract symptoms.

285 very had a protective association with lower urinary tract symptoms.

286 void) were positively associated with lower urinary tract symptoms.

287 and progression of clinically relevant lower urinary tract symptoms.

288 e of the most common and bothersome of lower urinary tract symptoms.

289 itulate several clinical components of lower urinary tract symptoms.

290 urethra in regulating reflexes in the lower urinary tract that depend on the state of the bladder.

291 thral sensory information plays in the lower urinary tract, the relationship between physiological ur

292 ry feedback plays in regulation of the lower urinary tract, there is little information about the cha

293 CuCl2 was not excreted or accumulated in the urinary tract, thus allowing thorough pelvic exploration

294 emic N1MS treatment eliminated bacteria from urinary tract tissues and serially collected urine sampl

295 CI, 1.19-1.71), respectively; and for upper urinary tract urothelial carcinoma recurrence, CSS and O

296 a proposed defender against infection of the urinary tract via its antimicrobial properties, but its

297 rasts with the attenuating effect of fimK on urinary tract virulence, illustrating that a single fact

298 The urinary tract was the only source of infection associate

299 bsequently ascend through the urethra to the urinary tract, where they cause UTIs.

300 tional release and accumulation of Fg in the urinary tract, which facilitated MRSA colonization.